The Opportunity
VRAI Heart is the immersive intelligence platform for cardiac ablation. We bridge Menlo Park (Silicon Valley) commercial strategy with French Clinical Excellence to transform the $3.5B cardiac navigation market. Today, labs are capped by manual 2D and external 3D mapping workflows withhigh redo rates. We solve this.

The Economic Engine: Margin Expansion
Because surgical tools are bundled into fixed hospital payments, profit is driven by efficiency. VRAI Heart delivers a sub-12-month ROI by:

25% Increase in Lab Capacity: Reducing procedure time by 20 minutes and slashing the 50% redo rate.
Cost Reduction: A "Mapping catheter-Free" workflow that saves $1,500–$3,000 in disposable costs per case.
Risk Mitigation: A 50% reduction in major complications (each event costing $15k up to $50k).
Future Moat: Capturing the "Optimized Path" data required for the $6B+ future of robotic EP surgery.

Commercial & Clinical Pull

The OEM: LOI signed with a European catheter manufacturer for global training simulators.
The Science: Liryc (Bordeaux CHU) is standing by to validate our capacity and safety metrics through animal trials once funding is secured. VRAI Heart is part of the Refer Rythmo network, providing access to future implementations

A Global Founding Team

Erwan Rivet (CEO): Menlo Park, CA. (US Strategy / Fund raising).
Dr. Mohannad Mafhoud (CMO): Evry, France. (Active EP Founder).
Dr. Heni Cherni (CTO): Tours, France. (AI / Immersive Architecture).

Immediate Milestone: The €100k "Activation Tranche"
We are seeking an initial €100k (of a €300k BSA AIR, 20% discount) by August to:

Activate OEM Production: Trigger the simulator order.
Activate Liryc: Initiate clinical trial design and safety validation in Bordeaux.
Hire Operations: Recruit a full-time Director of Operations in France.

The Ask
We are seeking a Syndicate Lead (€50k+) and participants starting at €25k via BSA AIR at a €4M Pre-money valuation.